Fig. 2: Blood sGPNMB level parallels the course of tumor response to ICI treatment. | Communications Medicine

Fig. 2: Blood sGPNMB level parallels the course of tumor response to ICI treatment.

From: Acquired resistance to immune checkpoint therapy is caused by glycoprotein non-metastatic melanoma protein B signal cascade

Fig. 2

a RCC patients (n = 39) were categorized into responders (Res) and non-responders (NR) based on 12-week evaluations after starting ICI. While most Res maintained a positive response (persistent Res or pRes), some Res acquired resistance (AR) to ICI. NR were sorted into those who never responded positively (pNR) and those who displayed a delayed positive response (acquired sensitivity or AS). Patient number in each category and frequency among total RCC cases are indicated. b Chronological changes (weeks after onset) in sGPNMB in each individual patient are shown, with red-dashed lines indicating the median sGPNMB value (11.3 ng/ml) of the stable disease (SD)/partial response (PR) group. Red and blue lines indicate a rise in transition to progressive disease (PD) and to PR, respectively. Note: pRes who displayed PR did not take many treatment cycles so that blood samples were not available at >36 weeks.

Back to article page